TRT and Testicular Atrophy: Prevention and Reversal
Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Testicular atrophy is a common TRT side effect due to HPG axis suppression. Prevention involves co-administering HCG (250-500 IU 2-3 times weekly). Reversal for existing atrophy uses more intensive HCG protocols (500-1000 IU 2-3 times weekly) or a full TRT restart.
TRT and Testicular Atrophy: Prevention and Reversal
Testosterone Replacement Therapy (TRT) can lead to testicular atrophy, or shrinkage, due to the suppression of the body's natural Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) production. These gonadotropins are essential for testicular function, and their suppression reduces testicular size and function [1]. Understanding these mechanisms and implementing preventative or reversal strategies is crucial for men on TRT.
The Mechanism of TRT-Induced Testicular Atrophy
Exogenous testosterone reduces pituitary signaling, decreasing LH and FSH secretion. LH stimulates Leydig cells for testosterone, and FSH supports Sertoli cells for spermatogenesis. Reduced LH and FSH lead to less testicular activity, decreased size, and reduced sperm production [2]. This HPG axis suppression is a direct consequence of TRT.
Prevention Strategies: Maintaining Testicular Size and Function
Preventing testicular atrophy on TRT primarily involves maintaining endogenous testicular stimulation, most effectively through co-administration of Human Chorionic Gonadotropin (HCG).
- Human Chorionic Gonadotropin (HCG): HCG mimics the action of LH, directly stimulating the Leydig cells in the testes. This stimulation helps maintain intratesticular testosterone (ITT) levels, which are critical for testicular health and spermatogenesis, and prevents the significant reduction in testicular size. Typical preventative dosing for HCG alongside TRT ranges from 250-500 IU administered subcutaneously two to three times per week [3]. This approach allows men to benefit from TRT while mitigating the atrophic effects on the testes.
- Clomiphene Citrate: Clomiphene citrate can be used off-label alongside TRT to stimulate endogenous LH and FSH, maintaining testicular function, particularly for men preserving fertility and avoiding injections. Its preventative efficacy is less established than HCG.
Reversal Strategies: Restoring Testicular Size After Atrophy
Reversal of TRT-induced testicular atrophy is often possible with timely intervention, primarily involving HCG, sometimes with other medications or temporary TRT cessation.
- HCG Monotherapy or Adjunctive Use: For existing atrophy, a more aggressive HCG protocol (500-1000 IU two to three times per week) can be initiated, often with TRT tapering or discontinuation. This stimulates Leydig cells to restore testicular volume, with improvements often seen within 3-6 months [4].
- TRT Restart Protocol: Complete reversal and natural function restoration may require a full TRT restart protocol (Article 7), discontinuing exogenous testosterone and using HCG and SERMs to kickstart the HPG axis, especially for men seeking fertility or preferring to be off TRT.
Prevention vs. Reversal: A Clinical Perspective
| Feature | Prevention of Testicular Atrophy | Reversal of Testicular Atrophy |
| :---------------- | :--------------------------------------------------------------- | :------------------------------------------------------------------- |
| Timing | Initiated concurrently with TRT | Initiated after atrophy has occurred |
| Primary Agent | HCG (250-500 IU 2-3x/week) | HCG (500-1000 IU 2-3x/week), sometimes with TRT cessation/tapering |
| Goal | Maintain testicular size and function, preserve fertility potential | Restore testicular size and function, regain fertility (if desired) |
| Complexity | Generally simpler, integrated into TRT regimen | More intensive, may require temporary TRT cessation |
| Outcome | Avoidance of atrophy, maintenance of ITT | Restoration of testicular volume, potential return of spermatogenesis |
Clinical Takeaway
Testicular atrophy is a common and often concerning side effect of TRT due to the suppression of the HPG axis. Prevention is best achieved by co-administering HCG at doses of 250-500 IU two to three times weekly alongside TRT, which maintains testicular stimulation and intratesticular testosterone. For men already experiencing atrophy, reversal is typically possible with more intensive HCG protocols (500-1000 IU two to three times weekly) or a full TRT restart. Early intervention and consistent adherence to adjunctive therapies are key to preserving testicular health and function while on or coming off TRT.